<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Previous studies have shown that 3-hydroxy-3-methylglutaryl <z:chebi fb="3" ids="15346">coenzyme A</z:chebi> (HMG-CoA) reductase inhibitors (<z:chebi fb="0" ids="35664">statins</z:chebi>) protect the brain against ischemic injury by upregulating endothelial nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase (eNOS) </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we tested the hypothesis that <z:chebi fb="0" ids="35664">statins</z:chebi> provide additional beneficial effects by also upregulating endogenous tissue plasminogen activator (tPA) and enhancing clot lysis in a mouse model of embolic focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Heterologous blood clots (0.2 mm) were injected into the distal internal carotid artery to occlude blood flow in the middle cerebral artery territory after long-term (14 days) <z:chebi fb="0" ids="9150">simvastatin</z:chebi>, <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> or vehicle treatment </plain></SENT>
<SENT sid="3" pm="."><plain>Ischemic lesion volume, neurologic deficits, as well as residual blood clots were measured at 22 h </plain></SENT>
<SENT sid="4" pm="."><plain>Reverse transcription-polymerase chain reaction assessed <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels of eNOS, tPA, and the endogenous plasminogen activator inhibitor PAI-1 </plain></SENT>
<SENT sid="5" pm="."><plain>Ischemic lesion volumes and neurologic deficits were significantly reduced in <z:mp ids='MP_0002169'>wild-type</z:mp> mice by both <z:chebi fb="0" ids="9150">simvastatin</z:chebi> and <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="35664">Statins</z:chebi> increased eNOS and tPA <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels but did not change <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels of PAI-1 </plain></SENT>
<SENT sid="7" pm="."><plain>In eNOS knockout mice, <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> reduced the volume of ischemic tissue and improved neurologic outcomes after <z:mp ids='MP_0006134'>arterial occlusion</z:mp> by blood clot emboli </plain></SENT>
<SENT sid="8" pm="."><plain>In contrast, <z:chebi fb="0" ids="35664">statins</z:chebi> did not have protective effects in tPA knockout mice after embolic focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, but only in a filament model where focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> was achieved via mechanical occlusion </plain></SENT>
<SENT sid="9" pm="."><plain>These results suggest that <z:chebi fb="0" ids="35664">statins</z:chebi> protect against <z:hpo ids='HP_0001297'>stroke</z:hpo> by multiple mechanisms involving both eNOS and tPA </plain></SENT>
<SENT sid="10" pm="."><plain>The involvement of each pathway may be revealed depending on the choice of experimental <z:hpo ids='HP_0001297'>stroke</z:hpo> model </plain></SENT>
</text></document>